In a 73‑year‑old woman with severe hypertension and stage 3‑4 chronic kidney disease currently taking irbesartan 150 mg, should irbesartan be administered once daily or twice daily?

Irbesartan Should Be Administered Once Daily

Irbesartan is ideally dosed once daily, not twice daily. The FDA-approved dosing for irbesartan is once-daily administration at 150-300 mg for hypertension and 300 mg for diabetic nephropathy 1. This recommendation is supported by clinical trial evidence demonstrating equivalent 24-hour blood pressure control with once-daily versus twice-daily dosing.

Evidence Supporting Once-Daily Dosing

FDA-Approved Dosing

The official FDA labeling explicitly states that irbesartan should be administered once daily, with a recommended initial dose of 150 mg that can be increased to 300 mg once daily as needed 1. For nephropathy in type 2 diabetic patients (relevant to your patient with stage 3-4 CKD), the recommended dose is 300 mg once daily 1.

Clinical Trial Data

A key ambulatory blood pressure monitoring study directly compared once-daily versus twice-daily irbesartan dosing 2. The study found that:

• 150 mg once daily provided equivalent 24-hour blood pressure control to 75 mg twice daily (same total daily dose)
• Mean 24-hour ambulatory diastolic blood pressure reductions were -7.2 mmHg for both 150 mg once daily and 75 mg twice daily
• Trough-to-peak ratios were ≥55% with 150 mg once daily, demonstrating sustained effect throughout the 24-hour dosing interval 2

The FDA label confirms these findings, noting that "once-daily dosing with 150 mg gave trough and mean 24-hour responses similar to those observed in patients receiving twice-daily dosing at the same total daily dose" 1.

Guideline Alignment

Major hypertension guidelines consistently recommend once-daily dosing to improve adherence:

• The 2020 ISH Guidelines explicitly state: "Simplify regimen with once daily dosing and single pill combinations" 3
• The 2024 ESC Guidelines recommend taking medications "at the most convenient time of day for the patient to establish a habitual pattern of medication taking to improve adherence" 4
• The 2017 ACC/AHA Guidelines list irbesartan with a daily frequency of "1" (once daily) at doses of 150-300 mg 5

Practical Application for Your Patient

For your 73-year-old woman with severe hypertension and stage 3-4 CKD currently on irbesartan 150 mg:

1. Continue once-daily dosing - This is the evidence-based approach
2. Consider dose escalation to 300 mg once daily if blood pressure remains uncontrolled, as this is the maximum approved dose and provides additional benefit without requiring split dosing 1
3. Add additional agents if needed rather than splitting the irbesartan dose - Guidelines recommend adding a calcium channel blocker or thiazide-like diuretic to ARB therapy in CKD patients 3, 6

Pharmacokinetic Rationale

Irbesartan has a sufficiently long half-life to maintain therapeutic blood pressure reduction over 24 hours with once-daily dosing. The drug demonstrates:

• Peak effects at 3-6 hours post-dose
• Sustained effect throughout the 24-hour period
• Approximately 60-70% trough-to-peak ratio, indicating consistent blood pressure control 1

There is no clinical advantage to twice-daily dosing and it reduces adherence without improving efficacy.